Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Nykode Therapeutics AS's current 3-Year Share Buyback Ratio was -3.50%.
The historical rank and industry rank for Nykode Therapeutics AS's 3-Year Share Buyback Ratio or its related term are showing as below:
STU:5VB'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -4.7 Med: -2.4 Max: -0.1
Current: -3.5
During the past 9 years, Nykode Therapeutics AS's highest 3-Year Share Buyback Ratio was -0.10%. The lowest was -4.70%. And the median was -2.40%.
STU:5VB's 3-Year Share Buyback Ratio is ranked better than 70.78% of 1191
companies
in the Biotechnology industry
Industry Median: -11.8
vs STU:5VB: -3.50
Nykode Therapeutics AS (STU:5VB) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Nykode Therapeutics AS 3-Year Share Buyback Ratio Related Terms
STU:5VB vs VRTX, REGN, RVMD: 3-Year Share Buyback Ratio Comparison
For the Biotechnology subindustry, Nykode Therapeutics AS's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nykode Therapeutics AS 3-Year Share Buyback Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nykode Therapeutics AS's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Nykode Therapeutics AS's 3-Year Share Buyback Ratio falls into.
Nykode Therapeutics AS 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of -3.50 mean?
Nykode Therapeutics AS (STU:5VB) has a 3-Year Share Buyback Ratio of -3.50 as of Mar. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Nykode Therapeutics AS and its competitors. According to the industry distribution chart, Nykode Therapeutics AS ranks #348 out of 1191 companies in the Biotechnology industry, placing it in the top 29.2%.
Is Nykode Therapeutics AS's 3-Year Share Buyback Ratio too high?
Nykode Therapeutics AS's current 3-Year Share Buyback Ratio is -3.50. Based on the distribution chart, Nykode Therapeutics AS ranks #348 out of 1191 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Nykode Therapeutics AS has a GF Score™ of 37/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Nykode Therapeutics AS's 3-Year Share Buyback Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nykode Therapeutics AS ranks #348 out of 1191 companies for 3-Year Share Buyback Ratio. This puts Nykode Therapeutics AS in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Biotechnology company?
A good 3-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Nykode Therapeutics AS and its competitors. Nykode Therapeutics AS's current 3-Year Share Buyback Ratio is -3.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nykode Therapeutics AS stock overvalued right now?
Based on GuruFocus' analysis, Nykode Therapeutics AS (STU:5VB) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.55, compared to a current price of €0.41 — trading 26.1% below its estimated fair value. The current 3-Year Share Buyback Ratio is -3.50. Nykode Therapeutics AS's overall GF Score™ is 37/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Nykode Therapeutics AS (STU:5VB), the current 3-Year Share Buyback Ratio is -3.50 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nykode Therapeutics AS (STU:5VB) Overvalued in 2026?
Based on GuruFocus' analysis, Nykode Therapeutics AS stock appears to be undervalued.
The current stock price of €0.41 is trading 26.1% below its estimated GF Value™ of €0.55.
GuruFocus considers Nykode Therapeutics AS to be Modestly Undervalued.
Key valuation signals for STU:5VB:
3-Year Share Buyback Ratio: -3.50
GF Value™: €0.55 vs. price of €0.41 (26.1% below fair value)
No single metric tells the full story. See the STU:5VB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nykode Therapeutics AS is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company is developing individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate therapeutics to treat cancers with a high unmet medical need using it's modular immunotherapy technology, specifically targeting antigens to Antigen Presenting Cells, which are essential for inducing rapid and long-lasting immune responses. It operates in United States of America.
37GF Score
Get the complete analysis for STU:5VB
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:5VB has been successfully added to your 
